PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Metsä Board Oyj (METSA.HE)
5.440.14 (-2.51%)
5.44 - 5.64
4.95 - 8.28
2.1K / 2.4K (Avg.)
-272.00 | -0.02
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
4.01%
Positive revenue growth while UPM.HE is negative. John Neff might see a notable competitive edge here.
1.21%
Gross profit growth under 50% of UPM.HE's 17.85%. Michael Burry would be concerned about a severe competitive disadvantage.
5.90%
EBIT growth below 50% of UPM.HE's 34.09%. Michael Burry would suspect deeper competitive or cost structure issues.
5.90%
Operating income growth under 50% of UPM.HE's 34.09%. Michael Burry would be concerned about deeper cost or sales issues.
23.81%
Net income growth at 50-75% of UPM.HE's 41.09%. Martin Whitman would question fundamental disadvantages in expenses or demand.
19.96%
EPS growth at 50-75% of UPM.HE's 36.00%. Martin Whitman would suspect a lag in operational efficiency or a higher share count.
19.96%
Diluted EPS growth at 50-75% of UPM.HE's 36.00%. Martin Whitman would question if share issuance or modest net income gains hamper progress.
3.17%
Share change of 3.17% while UPM.HE is at zero. Bruce Berkowitz would see if slight buybacks (or dilution) matter in the bigger picture.
3.17%
Slight or no buyback while UPM.HE is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
-100.00%
Both companies cut dividends. Martin Whitman would look for a common factor, such as cyclical downturn or liquidity constraints.
-43.93%
Negative OCF growth while UPM.HE is at 39.53%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-41.13%
Negative FCF growth while UPM.HE is at 82.57%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
-26.25%
Both companies have negative long-term revenue/share growth. Martin Whitman would question if the entire market or product set is shrinking.
-26.25%
Negative 5Y CAGR while UPM.HE stands at 23.08%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-29.91%
Both firms have negative 3Y CAGR. Martin Whitman would wonder if the entire market segment is in short-term retreat.
-32.08%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-32.08%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
139.50%
3Y OCF/share CAGR above 1.5x UPM.HE's 4.01%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
124.28%
Net income/share CAGR above 1.5x UPM.HE's 6.59% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
124.28%
Below 50% of UPM.HE's 344.75%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
152.97%
3Y net income/share CAGR 50-75% of UPM.HE's 264.98%. Martin Whitman might see a lagging edge in short-term profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-22.21%
Negative 3Y equity/share growth while UPM.HE is at 4.17%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-25.68%
Firm’s AR is declining while UPM.HE shows 10.96%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-2.01%
Inventory is declining while UPM.HE stands at 3.73%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
2.69%
Similar asset growth to UPM.HE's 2.97%. Walter Schloss finds parallel expansions or investment rates.
-0.51%
We have a declining book value while UPM.HE shows 4.11%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
0.26%
Debt shrinking faster vs. UPM.HE's 0.74%. David Dodd sees a safer balance sheet if it doesn't impair future growth.
No Data
No Data available this quarter, please select a different quarter.
-3.01%
We cut SG&A while UPM.HE invests at 0.00%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.